Recent Finacing
Recent Raise
Orlance develops MACH-1, a needle-free microparticle "gene gun" delivering DNA/RNA-coated particles into the epidermis to induce systemic and mucosal immunity for room-temperature-stable, low-dose vaccines, targeting a universal influenza vaccine.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor